The role of quantitative changes in the epxression of insulin receptor substrate-1 and nuclear ubiquitin in abnormal glycometabolism in the livers of KKay mice and the relative therapeutic mechanisms of Astragalus polysaccharide

International Journal of Molecular Medicine

Volumn 33, Issue 2, 2014, Pages 341-350

  Ye, Yan ^a   Deng, Tao ^a   Wan, Xin Yue ^a   Ouyang, Jing Ping ^b   Liu, Min ^b   Mao, Xian Qing ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Astragalus polysaccharide; Glycometabolism; Insulin receptor substrate 1; Ubiquitination

Indexed keywords

ASTRAGALUS POLYSACCHARIDE; GLUCOSE; HERBACEOUS AGENT; INSULIN RECEPTOR SUBSTRATE 1; POLYSACCHARIDE; TRIACYLGLYCEROL; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN RESISTANCE; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UBIQUITINATION; WESTERN BLOTTING;

ANIMALS; ASTRAGALUS PLANT; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIVER; MICE; MICE, INBRED C57BL; PLANT EXTRACTS; POLYSACCHARIDES; SIGNAL TRANSDUCTION; TRIGLYCERIDES; UBIQUITIN;

EID: 84893797158     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1580     Document Type: Article

References (34)

1. Boller S, Joblin BA, Xu L, et al: From signal transduction to signal interpretation: An alternative model for the molecular function of insulin receptor substrates. Arch Physiol Biochem 118: 148-155, 2012.
2. White MF: IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283: E413-E422, 2002.
3. Tamemoto H, Kadowaki T, Tobe K, et al: Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372: 182-186, 1994.
4. Draznin B: Molecular mechanisms of insulin resistance: Serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: The two sides of a coin. Diabetes 55: 2392-2397, 2006.
5. Gual P, Le Marchand-Brustel Y and Tanti JF: Positive and negative regulation of insulin signaling through IRS-1 phos-phorylation. Biochimie 87: 99-109, 2005.
6. Lee AV, Gooch JL, Oesterreich S, Guler RL and Yee D: Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3'-kinase inhibition. Mol Cell Biol 20: 1489-1496, 2000.
7. Chen W, Xia YP, Chen WJ, Yu MH, Li YM and Ye HY: Improvement of myocardial glycolipid metabolic disorder in diabetic hamster with Astragalus polysaccharides treatment. Mol Biol Rep 39: 7609-7615, 2012.
8. Wang N, Zhang D, Mao X, Zou F, Jin H and Ouyang J: Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetes. Mol Cell Endocrinol 307: 89-98, 2009.
9. Kallon S, Li X, Ji J, et al: Astragalus polysaccharide enhances immunity and inhibits H9N2 avian influenza virus in vitro and in vivo. J Anim Sci Biotechnol 4: 22, 2013.
10. Lu J, Chen X, Zhang Y, et al: Astragalus polysaccharide induces anti-inflammatory effects dependent on AMPK activity in palmitate-treated RAW264.7 cells. Int J Mol Med 31: 1463-1470, 2013.
11. Wu Y, Ou-Yang JP, Wu K, Wang Y, Zhou YF and Wen CY: Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B. Acta Pharmacol Sin 26: 345-352, 2005.
12. Mao XQ, Wu Y, Wu K, Liu M, Zhang JF, Zou F and Ou-Yang JP: Astragalus polysaccharide reduces hepatic endoplasmic reticulum stress and restores glucose homeostasis in a diabetic KKAy mouse model. Acta Pharmacol Sin 28: 1947-1956, 2007.
13. Saltiel AR and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001.
14. Pessin JE and Saltiel AR: Signaling pathways in insulin action: Molecular targets of insulin resistance. J Clin Invest 106: 165-169, 2000.
15. Iwatsuka H, Shino A and Suzuoki Z: General survey of diabetic features of yellow KK mice. Endocrinol Jpn 17: 23-35, 1970.
16. Hitman GA, Hawrami K, McCarthy MI, et al: Insulin receptor substrate-1 gene mutations in NIDDM; implications for the study of polygenic disease. Diabetologia 38: 481-486, 1995.
17. White MF: The IRS-signalling system: A network of docking proteins that mediate insulin action. Mol Cell Biochem 182: 3-11, 1998.
18. White MF: The IRS-signalling system in insulin and cytokine action. Philos Trans R Soc Lond B Biol Sci 351: 181-189, 1996.
19. Thirone AC, Huang C and Klip A: Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol Metab 17: 72-78, 2006.
20. Kubota N, Kubota T, Itoh S, et al: Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab 8: 49-64, 2008.
21. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ and Dohm GL: Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95: 2195-2204, 1995.
22. Björnholm M, Kawano Y, Lehtihet M and Zierath JR: Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 46: 524-527, 1997.
23. Krook A, Björnholm M, Galuska D, et al: Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49: 284-292, 2000.
24. Abe H, Yamada N, Kamata K, et al: Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 101: 1784-1788, 1998.
25. Taniguchi CM, Ueki K and Kahn R: Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 115: 718-727, 2005.
26. Song R, Peng W, Zhang Y, et al: Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature 494: 375-379, 2013.
27. Chen YC, Fueger PT and Wang Z: Depletion of PAK1 enhances ubiquitin-mediated survivin degradation in pancreatic β-cells. Islets 5: 22-28, 2013.
28. Kirk-Ballard H, Wang ZQ, Acharya P, et al: An extract of Artemisia dracunculus L. inhibits ubiquitin-proteasome activity and preserves skeletal muscle mass in a murine model of diabetes. PLoS One 8: E57112, 2013.
29. Conaway RC, Brower CS and Conaway JW: Emerging roles of ubiquitin in transcription regulation. Science 296: 1254-1258, 2002.
30. Muratani M and Tansey WP: How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4: 192-201, 2003.
31. Wadosky KM and Willis MS: The story so far: Post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. Am J Physiol Heart Circ Physiol 302: H515-H526, 2012.
32. Han L, Wang P, Zhao G, Wang H, Wang M, Chen J and Tong T: Upregulation of SIRT1 by 17β-estradiol depends on ubiquitin-proteasome degradation of PPAR-? mediated by NEDD4-1. Protein Cell 4: 310-321, 2013.
33. Kilroy G, Kirk-Ballard H, Carter LE and Floyd ZE: The ubiquitin ligase Siah2 regulates PPAR? activity in adipocytes. Endocrinology 153: 1206-1218, 2012.
34. Stravodimou A, Mazzoccoli G and Voutsadakis IA: Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer. PPAR Res 2012: 367450, 2012.